| __timestamp | Amphastar Pharmaceuticals, Inc. | Merck & Co., Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 28427000 | 7180000000 |
| Thursday, January 1, 2015 | 37065000 | 6704000000 |
| Friday, January 1, 2016 | 41199000 | 7194000000 |
| Sunday, January 1, 2017 | 43415000 | 9982000000 |
| Monday, January 1, 2018 | 57564000 | 9752000000 |
| Tuesday, January 1, 2019 | 68853000 | 9872000000 |
| Wednesday, January 1, 2020 | 67229000 | 13397000000 |
| Friday, January 1, 2021 | 60932000 | 12245000000 |
| Saturday, January 1, 2022 | 74771000 | 13548000000 |
| Sunday, January 1, 2023 | 73741000 | 30531000000 |
Igniting the spark of knowledge
In the ever-evolving world of pharmaceuticals, research and development (R&D) is the lifeblood of innovation. Over the past decade, Merck & Co., Inc. and Amphastar Pharmaceuticals, Inc. have demonstrated contrasting yet intriguing R&D investment strategies.
Merck, a global leader, has consistently allocated substantial resources to R&D, with expenditures peaking at approximately $30.5 billion in 2023, a staggering 325% increase from 2014. This commitment underscores Merck's dedication to pioneering breakthroughs in healthcare.
Conversely, Amphastar, a smaller player, has shown a steady yet modest growth in R&D spending, reaching around $74.8 million in 2022, marking a 163% rise since 2014. This reflects Amphastar's strategic focus on niche markets and incremental innovation.
These divergent paths highlight the diverse approaches within the pharmaceutical industry, where both giants and niche players contribute to the advancement of medical science.
Who Prioritizes Innovation? R&D Spending Compared for Merck & Co., Inc. and Insmed Incorporated
Analyzing R&D Budgets: Merck & Co., Inc. vs Apellis Pharmaceuticals, Inc.
Comparing Innovation Spending: Merck & Co., Inc. and ADMA Biologics, Inc.
Research and Development Expenses Breakdown: Merck & Co., Inc. vs Dynavax Technologies Corporation
Comparing Innovation Spending: Incyte Corporation and Amphastar Pharmaceuticals, Inc.
Comparing Innovation Spending: Sarepta Therapeutics, Inc. and Amphastar Pharmaceuticals, Inc.
Research and Development: Comparing Key Metrics for Halozyme Therapeutics, Inc. and Amphastar Pharmaceuticals, Inc.
Analyzing R&D Budgets: Opthea Limited vs Amphastar Pharmaceuticals, Inc.
Who Prioritizes Innovation? R&D Spending Compared for Bausch Health Companies Inc. and Amphastar Pharmaceuticals, Inc.
Amphastar Pharmaceuticals, Inc. or MannKind Corporation: Who Invests More in Innovation?
Who Prioritizes Innovation? R&D Spending Compared for Amphastar Pharmaceuticals, Inc. and Celldex Therapeutics, Inc.
R&D Insights: How Amphastar Pharmaceuticals, Inc. and Viridian Therapeutics, Inc. Allocate Funds